These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21822309)

  • 1. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.
    Sayan AE; Stanford R; Vickery R; Grigorenko E; Diesch J; Kulbicki K; Edwards R; Pal R; Greaves P; Jariel-Encontre I; Piechaczyk M; Kriajevska M; Mellon JK; Dhillon AS; Tulchinsky E
    Oncogene; 2012 Mar; 31(12):1493-503. PubMed ID: 21822309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
    Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
    BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
    Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
    Iida K; Sakai R; Yokoyama S; Kobayashi N; Togo S; Yoshikawa HY; Rawangkan A; Namiki K; Suganuma M
    Sci Rep; 2017 Dec; 7(1):17770. PubMed ID: 29259259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
    Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
    Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer.
    Akgül M; Baykan Ö; Çağman Z; Özyürek M; Tinay İ; Akbal C; Uras F; Türkeri L
    Arch Ital Urol Androl; 2021 Jun; 93(2):148-152. PubMed ID: 34286546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL.
    Yan J; Xu C; Li Y; Tang B; Xie S; Hong T; Zeng E
    J Cell Mol Med; 2019 Aug; 23(8):5518-5531. PubMed ID: 31240814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.
    Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T
    Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.
    Paccez JD; Vasques GJ; Correa RG; Vasconcellos JF; Duncan K; Gu X; Bhasin M; Libermann TA; Zerbini LF
    Oncogene; 2013 Feb; 32(6):689-98. PubMed ID: 22410775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
    Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
    Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skipping of exon 10 in
    Shen L; Lei S; Zhang B; Li S; Huang L; Czachor A; Breitzig M; Gao Y; Huang M; Mo X; Zheng Q; Sun H; Wang F
    Theranostics; 2020; 10(13):5719-5735. PubMed ID: 32483414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
    Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
    PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
    Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
    Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
    Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
    RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.
    Divine LM; Nguyen MR; Meller E; Desai RA; Arif B; Rankin EB; Bligard KH; Meyerson C; Hagemann IS; Massad M; Thaker PH; Hagemann AR; McCourt CK; Powell MA; Mutch DG; Fuh KC
    Oncotarget; 2016 Nov; 7(47):77291-77305. PubMed ID: 27764792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
    Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
    Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
    Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.